2025 is set to change the industry. The new administration is poised to challenge many existing processes. The question is whether they will be based on data-driven analysis or ideologies and beliefs.

Our guests address this concern along with the existing challenges CEOs face, particularly manufacturing processes.

Additionally, they discuss weight loss drugs, focusing on GLP-1s, with medical precision.

Host

⁠Lori Ellis⁠, Head of Insights, BioSpace

Guests

⁠Miguel Forte⁠, President, International Society for Cell & Gene Therapy; Board Member, ARM; CEO and Board Member, Kiji Therapeutics

⁠Ali Pashazadeh,⁠ Founder, Treehill Partners